Lee et al. showed that ERβ’s isoforms also play an essential role in PRAD [24]: ERβ1 was assessed as an anti-proliferative factor, whereas ERβ2 and ERβ5 were continuously expressed in high-grade prostate tumors [129]. Here, ESR2 is linked to prostate adenocarcinoma.